ETRADE Capital Management LLC lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 28.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,574 shares of the medical research company’s stock after selling 1,030 shares during the period. ETRADE Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $304,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Edwards Lifesciences Corporation by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after acquiring an additional 406,901 shares during the last quarter. BlackRock Inc. lifted its position in Edwards Lifesciences Corporation by 0.8% during the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after acquiring an additional 105,819 shares during the last quarter. State Street Corp lifted its position in Edwards Lifesciences Corporation by 1.7% during the 1st quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock worth $883,219,000 after acquiring an additional 157,844 shares during the last quarter. Alliancebernstein L.P. lifted its position in Edwards Lifesciences Corporation by 29.8% during the 1st quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock worth $598,890,000 after acquiring an additional 1,459,921 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Edwards Lifesciences Corporation by 161.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after acquiring an additional 3,277,726 shares during the last quarter. 82.08% of the stock is owned by institutional investors and hedge funds.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. Insiders sold a total of 176,901 shares of company stock valued at $20,191,196 in the last quarter. Corporate insiders own 2.13% of the company’s stock.

A number of research firms have weighed in on EW. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research report on Wednesday, June 7th. Cowen and Company reissued an “outperform” rating and set a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Bank of America Corporation boosted their target price on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Edwards Lifesciences Corporation currently has a consensus rating of “Buy” and a consensus target price of $120.75.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/etrade-capital-management-llc-has-304000-position-in-edwards-lifesciences-corporation-ew/1600805.html.

Shares of Edwards Lifesciences Corporation (EW) opened at 109.31 on Friday. The company has a market cap of $23.08 billion, a PE ratio of 33.15 and a beta of 0.64. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a 50-day moving average of $113.80 and a 200-day moving average of $109.37.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same quarter in the previous year, the company earned $0.76 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.